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In examining disease, we gain wisdom about anatomy and physiology and 
biology. In examining the person with disease, we gain wisdom about life.  
 
- Oliver Sacks 
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LIST OF ABBREVIATIONS 
 
cDNA* Complementary DNA 
CpG*  Cytosine-phosphate-guanine 
DBS  Deep brain stimulation 
DLB  Dementia with Lewy bodies 
DNA*  Deoxyribonucleic acid 
GCTA  Genome-wide complex trait analysis 
gDNA* Genomic DNA 
GWAS Genome-wide association study 
HTS  High throughput sequencing 
HWE  Hardy-Weinberg equillibrium 
LD  Linkage disequilibrium 
MAF  Minor allele frequency 
MPTP  1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine 
mRNA * Messenger RNA 
MRSE  Methylation-sensitive restriction enzyme 
OR  Odds ratio 
PCR*  Polymerase chain reaction 
PD  Parkinson's disease 
PD-D  Parkinson's disease dementia 
qPCR  Quantitative PCR 
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RIN  RNA integrity number 
RNA*  Ribonucleic acid 
SNP  Single-nucleotide polymorphism 
SN  Substantia nigra 
UKPDS United Kingdom Parkinson's Disease Society 
ΔCT*  Delta threshold cycle 
 
*On the first appearance in the text, the terms are spelled out in full, followed by the 
abbreviated form in parentheses, except for the common abbreviations marked here by 
an asterix. 
 
Note that for some terms used only once in the text, abbreviations are not listed here, 
but may still be indicated in parentheses if they are frequent in the literature. Genes are 
throughout the text referred to by their gene symbols in italicized uppercase letters. 
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SUMMARY IN ENGLISH 
Parkinson's disease is a common neurological disorder where the prevalence increases 
with age. The diagnosis is based on motor symptoms, namely slowness of movements, 
rigidity, tremor and balance problems, yet patients also suffer a range of other 
complaints, including cognitive decline and dementia. We may currently offer therapy 
that effectively alleviates some of the symptoms of Parkinson's disease, but without 
available treatment to target the cause of the disease, the condition typically follows a 
progressive course, severely affecting the quality of life of patients and their families. 
An improved understanding of the disease mechanisms on a molecular level is crucial 
for the development of new therapeutic strategies in the future. Mapping the genetic 
causes of the disease represents a key aspect of this effort. In recent years, a number of 
gene regions affecting the risk of Parkinson's disease have been identified through 
large-scale genetic investigations known as genome-wide association studies. This has 
represented a significant breakthrough, yet many open questions remain to be 
addressed before clinical medicine can take advantage of the results from these studies. 
The work presented in this thesis aims to shed further light on the genetic causes of 
Parkinson's disease by building upon the findings from genome-wide association 
studies. We first examined genetic risk-variants in patients and healthy controls in a 
material of more than 2500 participants from Norway and Sweden and found 
supportive evidence for an association with disease risk for 11 different gene regions. 
Next, we presented an effective study design for investigating such gene regions in 
detail in large sample sets by modern sequencing technologies. We then used this 
method as part of a study where we explored in depth a susceptibility region on 
chromosome 1, called PARK16. In the final study we investigated the relation 
between genetic risk variants in the SNCA gene and methylation, an epigenetic 
modification of the DNA molecule that regulates gene expression. We found evidence 
indicating that genetic susceptibility may be mediated through epigenetic mechanisms. 
Taken together, the studies presented in this thesis involve a broad range of methods 
and topics that are expected to become increasingly important in the genetic study of 
Parkinson disease, as well as other common diseases, in the years to come.  
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SAMMENDRAG PÅ NORSK (SUMMARY IN NORWEGIAN) 
Parkinsons sykdom er en nevrologisk lidelse, der forekomsten øker med alderen. 
Diagnosen stilles ut ifra motoriske symptomer med langsomme bevegelser, stivhet, 
skjelving og balanseproblemer, men sykdommen medfører også en rekke andre plager, 
inkludert utvikling av kognitiv svikt og demens. Vi har i dag behandling som effektivt 
lindrer noen av symptomene ved Parkinsons sykdom, men ingen terapi som er rettet 
mot sykdommens årsak og kan forhindre at tilstanden progredierer og forårsaker 
alvorlig tap av livskvalitet hos pasienter og pårørende. En bedre forståelse av 
sykdomsmekanismene på molekylært nivå er avgjørende for å kunne utvikle nye 
behandlingsstrategier i fremtiden. Kartlegging av sykdommens genetiske årsaker 
bidrar med viktig nøkkelkunnskap i dette arbeidet. I senere år har en rekke genområder 
som påvirker risikoen for Parkinsons sykdom, blitt identifisert gjennom storskala 
genetiske undersøkelser, kjent som helgenoms- assosiasjonsstudier. Dette har vært et 
vesentlig gjennombrudd, men mange åpne spørsmål må besvares før resultatene fra 
disse studiene kan få positive ringvirkninger for klinisk medisin. Arbeidet som 
presenteres i denne avhandlingen, dreier seg om å bygge videre på funn fra 
helgenoms- assosiasjonsstudier for å kaste nytt lys over genetiske årsaker til 
Parkinsons sykdom. Først har vi sett på forekomsten av genetiske risikovarianter hos 
pasienter og friske kontroller i et materiale med over 2500 deltakere fra Norge og 
Sverige.  Vi fant støtte for en assosiasjon med sykdomsrisiko for 11 ulike genområder. 
Videre har vi presentert et effektivt studiedesign for å undersøke slike assosierte 
genområder grundigere i store prøvematerialer med moderne sekvenseringsteknologi. 
Denne metoden har vi deretter anvendt som ledd i en studie der vi har kartlagt 
nærmere et risiko-område på kromosom 1, kalt PARK16. I den siste studien har vi sett 
på sammenhengen mellom genetiske risikovarianter i genet SNCA og metylering, en 
epigenetisk modifikasjon av DNA-molekylet som er med på å regulere i hvilken grad 
genet er uttrykt. Vi fant holdepunkter for at genetikken påvirker sykdomsrisiko 
gjennom mekanismer som involverer epigenetikk. Studiene som presenteres i denne 
avhandlingen, involverer samlet sett et bredt spekter av metoder og problemstillinger 
som forventes å bli sentrale innen genetiske studier av Parkinsons sykdom og andre 
vanlige sykdommer i årene som kommer. 
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1. INTRODUCTION 
 
1.1 A brief history of Parkinson's disease 
The disorder which came to be known as Parkinson's disease (PD) was first described 
formally by James Parkinson in his seminal 1817 paper "An essay on the shaking 
palsy" (Parkinson, 1817). Notably however, a broad range of historical accounts 
indicate that the syndrome has been recognized in humans from ancient times (Stern, 
1989, Raudino, 2012), and in certain cultures even successfully treated by plant 
medicine (Manyam, 1990). Parkinson's famous monograph is based on clinical 
descriptions of six patients he had either seen in his own medical practice or observed 
in the streets close to his home in London. Still, his account captures a remarkable 
range of clinical features including limb tremor, flexed posture, shuffling gait, 
asymmetry of symptoms and a progressive disease course. In addition he foresaw the 
future discovery of an anatomical substrate in the brain explaining the symptoms. The 
term "Parkinson's disease" was introduced around 1875 by Jean-Martin Charcot, the 
prominent clinician and professor often referred to as the father of modern neurology 
(Lees, 2007). Charcot distinguished the motor symptoms of PD from "palsy" or 
muscle weakness, recognizing all the features still used to define the Parkinsonian 
syndrome: Bradykinesia, rigidity, tremor and postural instability. 
 In 1912, Fritz Heinrich Lewy published his first works on the histopathology of 
PD, describing characteristic eosinophilic, intracellular inclusions in a range of nuclei 
in the brainstem and basal cerebrum (Lewy, 1912). The lesions were named "Lewy 
bodies" by Konstantin N. Tretiakoff, who five years later reported the combination of 
inclusions and neurodegeneration in the substantia nigra (SN) of PD patients 
(Tretiakoff, 1919). Rolf Hassler later confirmed this finding and refined the 
anatomical substrate of Parkinsonism to the SN pars compacta (Hassler, 1938). The 
combination of Lewy pathology and loss of SN pigmented neurons is still considered 
the pathological hallmark of PD, and both lesions are required for the definitive post-
mortem diagnosis (Gelb et al., 1999). 
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The next crucial milestone in the understanding of Parkinson's disease was the 
characterization of dopaminergic neuronal transmission in the basal ganglia. The 
studies of Arvid Carlsson and co-workers in the 1950s provided evidence that the 
catecholamine neurotransmitter dopamine had a specific role in the corpus striatum 
(Carlsson et al., 1958). Carlsson further reported that dopa, the molecular precursor of 
dopamine, was partly able to reverse pharmacologically induced Parkinsonian 
symptoms in animals (Carlsson et al., 1957). Herbert Ehringer and Oleh Hornykiewicz 
demonstrated reduced dopamine levels in the striatum in post-mortem tissue from PD 
patients (Ehringer and Hornykiewicz, 1960). Together with the clinical neurologist 
Walter Birkmayer, Hornykiewicz went on to test L-dopa injected intravenously in 
patients with Parkinsonism (Birkmayer and Hornykiewicz, 1961). The initial report 
described a striking effect, yet subsequent trials were less convincing and limited by 
pronounced side effects. The clinical breakthrough came in the late 1960s, when 
George Cotzias developed a therapeutic regime of slowly increasing oral doses of L-
dopa, combined with a peripheral dopa decarboxylase inhibitor (Cotzias et al., 1969b, 
Cotzias et al., 1969a, Yahr et al., 1969). The introduction of L-dopa as symptomatic 
treatment in PD drastically changed the prognosis for patients with the disorder, and 
has furthermore become an emblematic example of therapeutic advance following 
from a fruitful interplay between clinical neurology and basal molecular neuroscience. 
1.2 A modern concept of Parkinson's disease 
The clinical diagnosis of PD is currently based on the presence of a Parkinsonian 
motor syndrome, and exclusion of possible causes of secondary Parkinsonism, such as 
the use of antipsychotic drugs or cerebrovascular disease affecting the basal ganglia 
(Figure 1) (Gibb and Lees, 1988). However, the importance of non-motor symptoms, 
both for the scientific understanding of the PD phenotype and for the disease burden 
experienced by patients, has been increasingly recognised in recent years (Chaudhuri 
et al., 2011, Martinez-Martin, 2011). Prevalent non-motor symptoms in PD include 
obstipation, bladder dysfunction, sleep disturbances, orthostatic hypotension, 
depression, hallucinations and cognitive decline. 
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Figure 1. UK Parkinson's Disease Society Brain Bank clinical diagnostic criteria 
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According to currently accepted criteria, at least bradykinesia remains a "sine qua 
non"; a clinical feature common to all patients diagnosed with PD (Gibb and Lees, 
1988). Yet apart from this, there is a remarkable heterogeneity in the distribution, 
severity and progression rate of both motor and non-motor symptoms across 
individual patients.  This raises the fundamental question of whether it is really 
justified to consider PD as a distinct, single entity. With respect to the motor syndrome, 
PD subtypes such as tremor-dominant versus bradykinetic-rigid PD and postural 
instability/gait disorder (PIGD) have been proposed (Marras and Lang, 2013, 
Thenganatt and Jankovic, 2014). These motor profiles are to some extent also 
correlated with long-term prognosis, where tremor-dominant PD is associated with a 
milder disease course. Studies indicate that as many as 75% of PD patients develop 
dementia over the course of the disease, yet the temporal relation of cognitive decline 
to other symptoms varies considerably (Aarsland and Kurz, 2010). According to 
current criteria, patients with Parkinsonism and dementia are classified as having 
either PD with dementia (PD-D) or dementia with Lewy bodies (DLB) based on the 
timing of symptom onset (Dubois et al., 2007, Lippa et al., 2007). DLB is diagnosed 
when dementia is manifest before an arbitrary cut-off of one year after the onset of a 
Parkinsonian motor syndrome. 
The treatment of PD is essentially symptomatic. Evidence seems to support 
some degree of neuroprotective properties for the monoamine oxidase inhibitors 
(Olanow et al., 2009), but there is no available therapy to effectively alter the disease 
course. In the early phases of the disease, motor symptoms are usually well controlled 
by the administration of dopaminergic drugs. In later stages, a subset of patients will 
experience a narrowing of the therapeutic window with problematic fluctuations in 
motor function. Due to the development in advanced treatment modalities such as 
deep brain stimulation (DBS) and pump systems for continuous drug administration, 
effective symptomatic treatment can now be offered even to patients with significant 
motor complications (Volkmann et al., 2013). However, axial involvement, including 
disturbances of gait and balance, may still respond poorly to dopaminergic medication 
and DBS. These more treatment-resistant motor symptoms, in combination with the 
range of severe non-motor features, are currently emerging as the most debilitating 
and therapeutically challenging aspects of PD. 
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It is well established that the neurodegenerative process starts long before the 
onset of motor symptoms in PD (Kordower et al., 2013). Furthermore, there is also 
evidence that certain non-motor features, may precede the onset of a Parkinsonian 
motor syndrome, supporting the notion of a symptomatic, yet pre-motor phase of the 
disease (Lang, 2011). Pre-motor symptoms include hyposmia, obstipation and rapid 
eye movement sleep behaviour disorder (RBD), and represent early clinical 
manifestations of the same neurodegenerative process. Considering future efforts to 
develop disease-modifying therapies, patients in the pre-motor stage would be 
interesting candidates for inclusion in clinical trials. Taken together, several lines of 
evidence weigh in favour of a definition of PD that is less dependent on the motor 
syndrome alone, taking a broader understanding of the disease process into account. 
Initiatives are being taken to update the criteria for research purposes (Berg et al., 
2014). As pre-motor symptoms are largely unspecific, an earlier diagnosis may have to 
be supplemented by biomarkers. The development of reliable biomarkers, based on for 
example imaging techniques or biochemical assays, is therefore an important scientific 
aim for current PD research. 
1.3 The epidemiology of Parkinson's disease 
After Alzheimer's disease, PD is the second most common of the neurodegenerative 
disorders. The incidence and prevalence of PD have been investigated in a number of 
epidemiological studies, yet published figures vary considerably and direct 
comparisons are often hampered by differences in methodology and reporting 
(Wirdefeldt et al., 2011). In a 2011 review, Wirdefeldt et al. found that reported 
incidence rates ranged between 1.5 and 22 per 100 000 person years, and prevalence 
rates mostly between 100 and 300 per 100 000. Several reports have indicated a higher 
prevalence in men than in women, but other studies found no such gender difference. 
PD is rare before the age of 50 years, and a sharp increase is seen for both incidence 
and prevalence after the age of 60 (de Lau and Breteler, 2006). A frequently cited 
figure is an estimated PD prevalence of 1% for people over 60 years of age in 
industrialized countries (Nussbaum and Ellis, 2003). With a larger proportion of the 
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population surviving into old age, the total number of PD patients in the world has 
been projected to double in 25 years, reaching a total of nine million in 2030 (Dorsey 
et al., 2007). 
Sporadic PD is generally considered a complex disease, caused by an interplay 
between a range of genetic, environmental, and possibly stochastic factors. However, 
the genetic contribution to PD risk was historically not always recognized. In 1983, 
Langston et al. reported the cases of four patients who in the context of intravenous 
drug abuse injected the compound 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine 
(MPTP) and developed a severe, chronic Parkinsonian syndrome with response to L-
dopa (Langston et al., 1983). The selective toxicity of MPTP against dopaminergic 
cells provided opportunities for animal models and drew scientific attention towards 
the possibility of exogenous toxic agents causing PD. An extensive list of 
environmental and lifestyle exposures have been investigated in epidemiological 
studies of PD. In large systematic reviews, the evidence for specific environmental 
risk factors is generally scarce (Wirdefeldt et al., 2011, de Lau and Breteler, 2006). An 
inverse association with both smoking and coffee consumption has been consistently 
demonstrated across large studies. There is also suggestive evidence that pesticide 
exposure may increase PD risk, but the role of specific compounds is unclear. 
Regarding medication use, there are reports indicating that non-steroid inflammatory 
drugs (NSAIDs) and calcium channel blockers may be associated with a decreased 
risk of PD. 
The genetic contribution to complex disease is classically addressed in twin 
studies. Monozygotic twins are genetically identical, whereas dizygotic twins on 
average share half their genome. Environmental factors are assumed to be equally 
shared between all twin pairs. Consequently, a genetic contribution to disease risk 
should result in higher concordance rates for monozygotic than for dizygotic twins. 
Several early twin studies failed to show differences in concordance rates, but these 
were generally limited by small sample size and cross-sectional design (Johnson et al., 
1990). A significant genetic effect has later been shown in longitudinal twin studies, 
especially when asymptomatic dopaminergic dysfunction by [18F]dopa positron 
emission tomography (PET) has been introduced as a more sensitive endpoint to 
ascertain concordance rate (Burn et al., 1992). On repeated follow up, this approach 
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has increased the concordance gap between monozygotic and dizygotic twins to 75% 
versus 22% (Piccini et al., 1999). Studies of familial aggregation represent another 
approach to investigate the importance of genetics for disease risk. A 2008 meta-
analysis based on the highest-quality studies found that individuals with a first-degree 
relative with PD carried a relative disease risk of 2.9 (Thacker and Ascherio, 2008). 
Studies from Norway (Kurz et al., 2003), Sweden (Sundquist et al., 2006) and Iceland 
(Sveinbjornsdottir et al., 2000) have reported slightly higher estimations, but 
confidence intervals were overlapping with the meta-analysis. 
In addition to the available epidemiological evidence, the importance of 
genetics factors in the aetiology of PD has been firmly established by the identification 
of genetic loci implicated both in monogenic and sporadic forms of the disease from 
the 1990s and onwards, as detailed further in the following sections. 
1.4 Mendelian forms of Parkinson's disease and implications for pathogenesis 
At the time of Charcot, several neurologists believed PD to be inheritable, based on 
observations of familial cases. In the first half of the twentieth century, PD families 
were reported from a range of European countries. The first systematic family study of 
Parkinsonism was published in 1949 by Henry Mjönes, who based on clinical material 
from central Sweden argued for a dominant inheritance pattern in PD (Mjönes, 1949). 
Subsequently, however, inheritable forms of PD received little scientific attention until 
the 1990s when advances in genetic methodology made it feasible to identify disease 
loci in large kindreds. Over the last 20 years, a number of genes responsible for 
Mendelian PD have been identified by linkage analysis, or in later years by high 
throughput sequencing (HTS) methods (Bonifati, 2014, Klein and Westenberger, 
2012). Both autosomal recessive, autosomal dominant and X-linked inheritance 
patterns have been described in monogenic forms of Parkinsonism. While some of 
these genes give rise to a disease that resembles sporadic PD, others are characterized 
by a broader phenotype where Parkinsonism is only one of several features 
constituting a genetic syndrome. Genes causing Mendelian disease where 
Parkinsonism is the prominent symptom are summarized in Table 1. 
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Table 1 Monogenic forms of Parkinsonism 
Parkinsonism may also occur as a clinical feature across a wide range of genetic 
neurodegenerative disorders not listed here, including DNA repeat expansions, 
frontotemporal lobe degenerations, mitochondrial disorders, neurodegenerations with 
brain iron accumulation and several others.  
* The pathogenic relevance of some of the recently proposed dominant genes remains
to be determined in large independent studies.
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The identification of Mendelian PD genes has been crucially important for the 
understanding of PD pathogenesis. In the following, this development is illustrated by 
considering the examples of SNCA, PARK2 and LRRK2. 
1.4.1 SNCA - α-synuclein 
Two large kindreds originating from the village Contursi in southern Italy, with 
autosomal dominant PD affecting 41 individuals across four generations, were 
reported in 1990. The clinical phenotype resembled sporadic PD, but with earlier onset, 
and typical PD pathology with Lewy bodies was observed on autopsy (Golbe et al., 
1990). The PD phenotype was mapped to chromosome 4q21-23 (Polymeropoulos et 
al., 1996), and a causative missense mutation was identified in SNCA (c.157G>A,  
p.Ala54Thr), which also segregated with disease in three Greek families with a similar
PD phenotype and inheritance pattern (Polymeropoulos et al., 1997). This was the first
genetic cause of PD to be recognized, and the starting point for extensive subsequent
research into α-synuclein as a key protein in the pathogenesis of PD.
Later studies have identified another five rare, pathogenic missense mutations 
in SNCA (Kruger et al., 1998, Zarranz et al., 2004, Lesage et al., 2013, Proukakis et al., 
2013, Pasanen et al., 2014). Furthermore, autosomal PD has also been found to be 
caused by SNCA multiplications. A severe phenotype with early onset, rapid 
progression and dementia was associated with SNCA triplication in the large "Iowa 
kindred" (Spellman, 1962, Muenter et al., 1998, Singleton et al., 2003), as well as a 
Swedish-American family with triplication of independent genetic origin (Farrer et al., 
2004). Screening for SNCA multiplications in dominant PD also revealed families with 
duplications (Chartier-Harlin et al., 2004, Ibanez et al., 2004). Duplications tend to 
give rise to a milder form of the disease as compared to triplication, pointing towards a 
dose dependent relationship between copy number and phenotype (Farrer, 2006). 
Following the discovery of SNCA mutations in PD, studies using 
immunohistochemical staining revealed it's corresponding protein, α-synuclein, as the 
main component of Lewy bodies (Spillantini et al., 1997). The application of α-
synuclein antibodies to visualise protein deposition in pathological tissue sections has 
been of great importance in PD research, leading to an increased understanding of the 
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widespread pathologies in different parts of the nervous system as the disease 
progresses. An influential hypothesis presented by Braak et al. is based on 
pathological staging of PD lesions (Braak et al., 2003). It proposes that the pathology 
spreads in a stereotypic pattern, possibly originating in the gut or nose, explaining the 
successive onset of different symptoms. Depositions of α-synuclein have further been 
identified in a range of other neurodegenerative disorders, both in the form of Lewy 
pathology and different histopathological patterns. These observations have had 
important implications for our understanding of the interconnections between 
degenerative brain disorders and have placed PD in a special relation to the broader 
group of synucleinopaties (Goedert, 2001, Jellinger, 2003). 
The normal function of α-synuclein is not fully understood, but evidence 
supports a role in the recycling of synaptic vesicles (Bendor et al., 2013). The protein 
exists naturally in an unfolded state, but has the potential to misfold, oligomerize and 
aggregate (Vekrellis et al., 2011). Understanding the mechanisms that determine the 
toxicity and spread of α-synuclein is currently a scientific aim receiving high priority 
across the PD field. Compelling evidence indicate that there may be mechanisms by 
which α-synuclein aggregation may self-propagate across cell membranes causing the 
pathology to spread from an initial "seeding" event to neighbouring neurons. This is 
also consistent with the observation that fetal neurons that have been transplanted into 
the striatum of PD patients in clinical trials, develop Lewy pathology despite the 
remarkably short lifespan of the grafted cells themselves (Li et al., 2008, Kordower et 
al., 2008). 
1.4.2 PARK2 - parkin 
Homozygous deletions the parkin gene (PARK2) were originally identified in a 
consanguineous Japanese family with juvenile-onset Parkinsonism (Kitada et al., 
1998), representing the first autosomal recessive form of PD to be genetically 
characterized. Parkin was functionally found to have protein-ubiquitin ligase activity 
(Shimura et al., 2000). Collectively, the discoveries of the recessive genes parkin, 
PINK1 and PARK7 (DJ-1) have highlighted the role of mitochondrial function, 
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oxidative stress and protein degradation pathways in PD pathogenesis (Dodson and 
Guo, 2007, Pickrell and Youle, 2015). 
Parkin mutations are rare overall, yet represent a major fraction of early-onset 
cases with a recessive inheritance pattern (Lucking et al., 2000). The clinical 
presentation is typically characterized by marked dystonia and steady progression of 
motor symptoms with early fluctuations, yet relatively intact cognitive function (Khan 
et al., 2003). Neuropathologically, most cases of parkin disease differ from SNCA 
mutations and sporadic PD by exhibiting isolated loss of dopaminergic neurons 
without accompanying Lewy pathology (Poulopoulos et al., 2012). The distinguishing 
features unique to recessive forms of Parkinsonism are important reminders of how the 
range of syndromes commonly classified as PD probably have markedly 
heterogeneous molecular underpinnings. 
1.4.3 LRRK2 - leucine-rich repeat kinase 2 
A second gene for autosomal dominant PD was identified in 2004 (Zimprich et al., 
2004, Paisan-Ruiz et al., 2004). Patients with LRRK2 mutations have been described 
with variable clinical and neuropathological characteristics, often indistinguishable 
from sporadic PD. Large screening efforts have demonstrated LRRK2 as the most 
frequent form of monogenic parkinsonism worldwide (Healy et al., 2008), with the 
G2019S mutation standing out as the most common (Kachergus et al., 2005). The 
fraction of PD cases caused by LRRK2 G2019S mutations is particularly high in 
Ashkenazi Jewish and North-African Arab populations, in the latter explaining over a 
third of sporadic cases and an even larger proportion of familial disease (Correia 
Guedes et al., 2010). Among other important insights, studies of LRRK2 in PD have 
demonstrated that monogenic disease can be common in particular populations, appear 
sporadically and have incomplete penetrance, probably modulated by other genetic 
and environmental factors (Trinh et al., 2014). 
26 
1.5 The genetic study of sporadic Parkinson's disease 
1.5.1 General aspects of complex genetics 
Although valuable insights have resulted from the investigation of Mendelian PD 
genes, the vast majority of patients have sporadic disease, caused by a complex 
interplay of both genetic and non-genetic factors. Progress in the study of complex 
genetics has followed a similar course for many common, non-communicable diseases 
over the last decades, led on by advances in technology and collaborative efforts to 
develop crucial database resources, such as the Human Genome Project (Lander, 2011, 
Lander et al., 2001), the International HapMap Project, the 1000 Genomes Project 
(1000 Genomes Project Consortium et al., 2010) and the Encyclopedia of DNA 
Elements (Encode Project Consortium, 2004). Consequently, the opportunities and 
challenges highlighted in the context of sporadic PD in this thesis, are to a large degree 
paralleled across a broad range of disorders. 
The genetic study of complex disease has several aims. Firstly, the 
identification of genetic risk loci may pave way for an improved understanding of 
pathogenic molecular mechanisms. Genes implicated in disease susceptibility are 
likely to encode proteins that participate in relevant cellular pathways. Mapping of 
disease-related genes, pathways and networks generates hypotheses for further 
functional research, and may eventually open new possibilities for therapeutic 
developments. A second type of aim concerns the utility of genetic information in the 
assessment of individual patients. Comprehensive knowledge about the genetic 
architecture of common diseases could conceivably allow for some degree of 
prediction or identification of individuals at risk. In combination with clinical 
outcomes, an individual genetic profile could also be useful in distinguishing 
subgroups of patients with similar characteristics. This strategy could have 
implications for the selection of patients to future clinical trials and would also be in 
line with the proposed ideal of tailored, personalized medicine. 
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1.5.2 Early candidate studies in sporadic Parkinson's disease 
The paradigmatic study design for identification of risk-loci in complex disease is the 
case-control association study. The earliest phase of association studies followed a 
candidate approach, and the available technology favoured microsatellites as the most 
convenient class of polymorphism for genotyping. From the late 1990s and onwards, a 
large body of publications established the Rep1 (D4S3481) mixed dinucleotide repeat 
upstream of SNCA as a susceptibility variant in sporadic PD, importantly 
demonstrating the principle that one locus can be implicated both in Mendelian and 
complex forms of the same disease (Kruger et al., 1999, Maraganore et al., 2006). 
The microtubule-associated protein tau is a main component of neurofibrillary 
tangles, a histopathological lesion seen in several neurodegenerative disorders 
commonly referred to as tauopathies, and distinct from the synuclein-dominant Lewy 
pathology of classical PD. However, missense and splicing mutations in the tau gene 
MAPT were shown to cause a combined phenotype of frontotemporal dementia and 
parkinsonism (Hutton, 2001). This and other findings, prompted the investigation of 
MAPT as a candidate gene for sporadic PD. MAPT is located on a region of 
chromosome 17 where a large inversion event has given rise to two distinct haplotype 
groups termed H1 and H2, which do not recombine. A number of studies have 
corroborated that the H1 haplotype carries an increased PD risk, although the 
responsible functional mechanism remains unclear (Martin et al., 2001, Skipper et al., 
2004). Importantly, the identification of MAPT as a susceptibility gene in PD has 
contributed to our current understanding of the interrelations and overlaps between 
different neurodegenerative disorders. 
1.5.3 GBA mutations 
Pathogenic mutations in GBA, encoding the enzyme glucocerebrosidase, cause 
Gaucher disease, an autosomal recessive lysosomal storage disorder. The clinical 
phenotypic spectrum of Gaucher disease includes Parkinsonism, and attentive 
clinicians involved in the follow-up of Gaucher patients came to suspect an 
overrepresentation of PD amongst the patients' relatives (Goker-Alpan et al., 2004). 
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Following the original publication, a number of studies have established heterozygous 
GBA mutations as strong risk factors for PD, highlighting the importance of lysosomal 
pathways in the pathogenesis (Sidransky et al., 2009). Furthermore, the gene has 
become a textbook example of rare variants with a large effect, representing an 
intermediate between rare Mendelian mutations with high penetrance and common 
alleles typically carrying a very small effect on risk. 
1.5.4 Rationale for genome-wide association studies 
The potential of candidate gene association studies depends on our ability to identify 
good candidates. Consequently, genetic discovery will rarely be able to uncover 
completely new pathways based on this approach. Furthermore, if a large number of 
candidate genes are investigated in small single studies, some will turn out positive by 
chance. These limitations posed major challenges in the early phases of complex 
disease genetics, and published associations were frequently not reproduced when 
independent follow-up studies were performed (Ioannidis et al., 2001). In contrast, the 
genome-wide association study (GWAS) represents a hypothesis-free approach to 
complex genetics, which has dominated the field from 2005 and onwards (Hirschhorn 
and Daly, 2005, McCarthy et al., 2008). 
The methodology of GWAS is based on a case-control design where a vast 
number of single-nucleotide polymorphism (SNP) markers spread across the genome 
are genotyped in each subject. Advances in array technology in the 2000s enabled 
large-scale parallelization of genotyping, typically investigating from 500 000 up to 
several million SNPs on the same chip. These markers are selected to maximize the 
genetic information captured based on knowledge about common haplotype structures. 
Genetic variants that tend to be inherited together are in linkage disequilibrium (LD). 
Stretches of high LD typically occur in regions of low recombination, whereas 
recombination hotspots divide chromosomes into haplotype blocks. The pattern of LD 
across the genome in different populations has been systematically characterized 
through the human HapMap-project, providing a crucial foundation for marker 
selection to GWAS genotyping arrays (International HapMap Consortium, 2003, 
International HapMap Consortium, 2005). Consequently, although the functionally 
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relevant genetic variants may not be directly investigated, the association signal will 
often still be captured by virtue of high LD with a genotyped SNP, tagging the 
functional variant. 
When allele frequency for a given SNP differs significantly between patients 
and healthy controls, it suggests that genetic variation affecting disease risk is present 
within the relevant LD block. However, given the multitude of SNPs genotyped in 
GWAS, association analysis may involve several million independent statistical tests, 
rendering the method vulnerable to false positives by random effects. Statistical 
significance levels in GWAS are therefore adjusted for multiple testing. A widely 
accepted threshold for genome-wide significance is 5x10-8. To achieve statistically 
robust results below this level, sample size is crucial. Thus, the establishment of large 
collaborative international consortia has been essential for successful GWAS. 
Combining several GWAS in meta-analysis has emerged as an important 
strategy to boost discovery. Where the included SNPs may vary across original studies 
due to differing genotyping platforms, compatible data sets may be obtained by 
imputation (Marchini et al., 2007). Based on comparison with comprehensive phased 
sequence data from a relevant database source such as the 1000 genomes project, 
imputation employs bioinformatic algorithms to infer the most likely alleles for SNPs 
that are not directly genotyped. This process greatly increases the density of SNP data, 
improving the sensitivity to association signals even from low-frequency variants. 
However, imputation also introduces a possible source of bias, especially if the 
reference population is not representative for the imputed dataset. 
1.5.6 Genome-wide association studies in Parkinson's disease 
Initial GWAS in PD were underpowered to detect signals passing a stringent 
significance threshold (Maraganore et al., 2005, Fung et al., 2006, Evangelou et al., 
2010). In 2009, the first genome-wide significant hits in PD were reported, from 
Caucasian and Japanese populations respectively (Simon-Sanchez et al., 2009, Satake 
et al., 2009). The findings confirmed SNCA as a risk-locus in both populations, and 
MAPT in Caucasians. In addition, three further loci were identified in the Japanese 
study, including BST1, PARK16 and LRRK2. Several more GWAS studies followed, 
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partly replicating these findings, and also adding novel loci to the list such as GAK and 
HLA (Hamza et al., 2010, Edwards et al., 2010, Saad et al., 2011, Spencer et al., 2011). 
The first PD GWAS based on meta-analysis and imputation was published by 
the International Parkinson's Disease Genomics Consortium in 2011 (Nalls et al., 
2011). It was followed by several similar studies (International Parkinson's Disease 
Genomics Consortium and Wellcome Trust Case Control Consortium, 2011, Pankratz 
et al., 2012), and also a GWAS using recruitment of subjects over the internet to 
obtain a large sample size (Do et al., 2011). Collectively, these efforts greatly 
expanded the list of nominated risk loci. The cumulative increase in genome-wide 
significant association signals for PD between 2009 and 2012 is summarized 
graphically in Paper 1, Figure 1. At the outset of the work described in this thesis, 20 
GWAS loci were identified in PD. Seven of these had not been investigated further in 
independent follow-up studies. 
1.5.7 Challenges and unresolved issues for the genetics of sporadic Parkinson's 
disease 
Large-scale GWAS have represented a breakthrough in PD genetics by linking a range 
of  previously unknown loci across the genome to disease risk by means of robust 
statistical association. However, considerable knowledge gaps need to be filled before 
translational research and clinical medicine can benefit significantly from such a list of 
genetic loci. Dedicated follow-up studies, building upon the findings from GWAS, are 
warranted in order to address a number of unresolved issues.  
The variability in disease risk that is accounted for by significant GWAS loci 
constitutes only a small fraction of the total estimated heritability of PD. This 
phenomenon, commonly referred to as "missing heritability", has been a general 
feature of the GWAS era in complex genetics (Maher, 2008, Manolio et al., 2009). A 
range of hypotheses have been proposed to suggest possible sources of genetic 
variability not readily detected in GWAS, such as rare variants, structural variation, 
allelic heterogeneity, gene-environment interaction and gene-gene interaction, also 
termed epistasis. Dedicated methodologies and study designs must target these 
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hypotheses in order to gain a comprehensive understanding of the genetic architecture 
of PD. 
A major aim of GWAS is to identify disease-relevant genes. However, 
associated SNPs are typically located in non-coding genomic regions, within 
haploblocks of high LD that often encompass several genes. Although one might 
sometimes speculate based on available knowledge about protein function, it 
frequently remains an open question precisely which gene is responsible for an 
association signal. This uncertainty represents a barrier towards modelling of disease 
pathways and functional studies linking genetic findings to pathogenesis (Ioannidis et 
al., 2009). Refining our understanding of implicated genes and causal mechanisms 
behind GWAS signals will be an important step before the findings from large-scale 
genetic studies can be of greater benefit to neighbouring fields of research and 
ultimately inspire translational studies aiming for improved therapy. 
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2. AIMS OF THE STUDY
The principal aim of genetic studies in sporadic PD is to uncover important insights 
about pathogenic mechanisms, with improvement of therapeutic strategies as the 
ultimate goal. The aim of the present work was to refine and expand our understanding 
of the association signals reported in GWAS of PD. This was sought, firstly, by 
replication of GWAS signals in a Scandinavian population and development of an 
effective pooled sequencing study design suitable for variant screening in GWAS loci. 
Subsequently, we concentrated on two specific loci, performing fine mapping and 
targeted resequencing of the PARK16 locus and assessing GWAS SNPs in relation to 
DNA methylation and mRNA expression in SNCA. 
Aim of paper 1: In this paper, we sought to contribute further evidence regarding 
genetic loci reported in GWAS of sporadic PD and examine the distribution of 
association signals in a relatively homogeneous Scandinavian population. 
Aim of paper 2: In this paper we aimed to develop and report an effective study 
design for targeted resequencing in large patient cohorts. We investigated monogenic 
PD genes as an example target to demonstrate the effectiveness and reliability of the 
method, yet proposing that the same approach is equally suitable for examination of 
GWAS loci. 
Aim of paper 3: In this paper, we aimed to shed further light on the PARK16 
association signal. We combined the sequencing approach described in Paper 2 and 
genotyping of a fine-mapping SNP panel to identify both common and low-frequency 
variation potentially affecting disease risk. Based on our data we explored previously 
proposed hypotheses about the PARK16 locus. 
Aim of paper 4: In the last paper, we hypothesized that susceptibility SNPs in SNCA 
might correlate with DNA methylation in the promoter region, previously shown to be 
decreased in PD. We tested this hypothesis by investigating GWAS SNP genotypes, 
methylation levels and mRNA expression levels in blood and brain tissue. 
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3. SUMMARY OF RESULTS
Paper 1. Supportive evidence for 11 loci from genome-wide association studies in 
Parkinson's disease 
The list of  PD risk-loci reported at genome-wide significance levels has expanded 
steadily from 2009 and onwards. In particular, the larger datasets achieved by 
imputation and meta-analysis of multiple smaller GWAS have led to higher numbers 
of positive findings. To further increase the evidence related to various GWAS-linked 
loci in PD and examine the distribution of association signals in a relatively 
homogenous Scandinavian sample set, we performed a replication study of 1345 PD 
patients and 1225 control subjects from Norway and Sweden. We genotyped a panel 
of SNPs representing 18 loci previously reported at genome-wide significance levels, 
as well as four near-significant, suggestive loci. Testing for association in a logistic 
regression model, we replicated 11 loci at nominal significance level (p<0.05) (SNCA, 
STK39, MAPT, GPNMB, CCDC62/HIP1R, SYT11, GAK, STX1B, MCC1/LAMP3, 
ACMSD and FGF20). Stratifying patients according to a cumulative genetic risk 
profile across all these loci, we found a threefold increase in PD risk for the highest 
versus the lowest score quintile. 
Paper 2. Effective variant detection by targeted deep sequencing of DNA pools: 
an example from Parkinson's disease 
While the GWAS design is appropriate for the common disease-common variant 
scenario, resequencing studies will be necessary to clarify the role of rare variants in 
sporadic PD and other complex disorders. In this article, we present a study design for 
cost-effective variant detection in large cohorts by targeted deep sequencing of DNA 
pools. We investigated samples from 387 PD patients, sequenced in pools representing 
10 individuals each. A 200kb custom HaloPlex target enrichment kit was used to 
capture DNA from coding exons of 71 genes relevant to PD and other 
neurodegenerative disorders, including all PD GWAS loci. In this paper we focused on 
the analysis of six genes implicated in Mendelian PD, emphasizing quality metrics and 
evaluation of the method. We detected a total of 17 rare, nonsynonymous variants in 
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these genes and observed a sensitivity of 97% and specificity of 94% in our 
experiment when pooled sequencing results were validated against individual 
genotyping and Sanger sequencing. 
Paper 3. Fine mapping and resequencing of the PARK16 locus in Parkinson's 
disease 
The PARK16 locus, entailing five genes on chromosome 1, was among the first 
regions to be implicated in sporadic PD through GWAS, originally in a Japanese study. 
The implicated gene(s) and location of functionally relevant variants remain currently 
unknown, although a few hypotheses have been presented, including a proposed gene-
gene interaction between risk alleles of the PARK16 gene RAB7L1 and LRRK2. We 
genotyped a fine-mapping panel of 17 SNPs spanning the PARK16 locus in the case-
control sample set available from the Paper 1 study and found supportive evidence for 
an association signal near the 5' region of RAB7L1, both in single-SNP and sliding 
window haplotype analysis. As this signal is in low LD with the top-hit from the 
largest meta-analysis in Caucasians, we argue in favour of allelic heterogeneity. In 
explorative epistasis-analysis we found suggestive support for an interaction with 
LRRK2. In pooled sequence data from the experiment described in Paper 2, we found 
no evidence of rare coding variants contributing to the PARK16 association signal. 
Paper 4. Parkinson's disease correlates with promoter methylation in the α-
synuclein gene 
Given the pivotal role of SNCA in PD pathogenesis, we aimed to increase the 
understanding of common association signals at this locus. Previous studies have 
found evidence that DNA methylation levels of a putative promoter in SNCA intron 1 
correlate with PD. We hypothesized that methylation is affected by genetic variation, 
possibly representing a functional mechanism mediating the effects detected in GWAS. 
We genotyped GWAS SNPs and assessed methylation levels by methylation-sensitive 
restriction enzyme (MSRE) digestion and quantitative PCR (qPCR) in a case-control 
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blood sample set (N=72). Intron 1 methylation levels were decreased in PD compared 
to controls and significantly associated with genotype of a GWAS SNP near the 5' end 
of SNCA. The methylation quantitative-trait locus (mQTL) finding was replicated in a 
smaller sample set from cerebral cortex (N=24). We detected no significant 
associations with SNCA mRNA levels. 
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4. METHODOLOGICAL CONSIDERATIONS
4.1 Subjects 
Recruitment of study subjects and collection of blood samples to a registered biobank 
for Parkinsonism at Oslo University Hospital have been performed from 2007 and 
onwards. Patients were asked to participate in the study during clinical visits at two 
different hospitals within the larger Oslo region. The majority of patients were 
recruited from the Department of Neurology at Oslo University Hospital (mainly M. 
Toft), a tertiary care centre for movement disorders, where patients are referred mostly 
for diagnostic second opinion or evaluation for advanced treatment options, including 
DBS. Consequently, this patient group is carachterized by an overrepresentation of 
early onset and severe motor fluctuations, yet better preserved cognitive function as 
compared to the average PD cohort.  The remaining fraction of PD subjects was 
included at Drammen Hospital (K. A. Bjørnarå). This is a secondary centre where the 
age distribution and symptomatology of PD patients reflect a general neurological 
outpatient practice. Control subjects have been recruited among spouses of patients, 
volunteers from Rotary clubs in the Oslo area and outpatients in primary care without 
neurological disease (mainly L. Pihlstrøm). A total of 405 patients and 464 control 
subjects from Oslo (including Drammen) were included in the final analyses of Paper 
1 and Paper 3. The blood samples used in Paper 2 and Paper 4 both represent subsets 
of this same case-control cohort. 
For Paper 1 and Paper 3, four other centres in Norway and Sweden were 
invited to contribute samples to a collaborative Scandinavian association study. 
Samples from Oslo, the ParkWest study in Western Norway, Gothenburg, Linköping 
and Umeå combined into a total of 1380 PD patients and 1295 controls. Details of 
recruitment and demographic characteristics across study sites are summarized in 
Paper 1 (Table 1 and Table 2). The variability in age at onset of PD reflects how 
patients were recruited in different clinical settings. The Oslo series, dominated by a 
highly specialized clinic, had the earliest mean age at onset, 54 years. At the other 
extreme was the ParkWest cohort, with average onset at 67 years. This is an incidence-
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based study, designed to include a representative cohort of novel cases from four 
counties in southwestern Norway (Alves et al., 2009). 
Strict definition of phenotypes and rigorous patient ascertainment are important 
ideals in clinical genetic research. Several sets of diagnostic criteria for PD are 
currently in use. The ParkWest study used the criteria by Gelb et al. (Gelb et al., 1999), 
whereas the other four sites based diagnosis upon a variant of the United Kingdom 
Parkinson's Disease Society Brain Bank Criteria (Gibb and Lees, 1988). Regardless of 
the criteria of choice, even in the hands of expert neurologists the concordance 
between a clinical diagnosis of PD and classic Lewy pathology on post mortem 
examination is far from perfect (Litvan et al., 1998). This diagnostic inaccuracy 
represents a limitation that is likely to reduce the statistical power in genetic 
association studies. Conversely, there may also be subjects included in the control 
group which eventually go on to develop PD, or have incidental Lewy body disease 
without symptoms. However, given that PD patients represent a minor fraction within 
a random sample of elderly, such misclassification of subjects can be expected to be 
tolerably low (Moskvina et al., 2005). The control subjects in the present study were 
all above 40 years of age and did not have any known neurological disease or first-
degree relative with Parkinsonism. Ideally, clinical neurological examination of all 
controls might have excluded some subjects based on subtle clinical signs, yielding a 
"supernormal" control cohort and theoretically slightly improved statistical power. 
In addition to blood samples from Norway and Sweden used in Papers 1-4, 
Paper 4 also included 24 samples of human frontal cortex, provided by the Banner Sun 
Health Research Institute.  
4.2 Ethical considerations 
All participants gave written, informed consent. The study was approved by the 
Regional Committee for Medical Research Ethics (Oslo, Norway), and sample and 
data collection at each study site was approved by local ethics committees. The 
consent form for the Oslo study site covers research into genetic causes of 
Parkinsonism. Patients were actively informed that genetic analyses would be 
performed for research purposes only, and that no results would be given back. Only 
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personnel directly involved in subject recruitment have had access to patient identity. 
Anonymized IDs were used in all sample handling, experiments and analyses, and data 
are stored on secure servers dedicated to research databases at Oslo University 
Hospital.  
4.3 DNA and RNA extraction and quality measures 
A range of different methods are currently available to extract quality DNA from 
blood and body tissues, and methodological details are often omitted from scientific 
papers. However, degraded DNA or highly variable input concentrations may 
adversely affect the performance of genetic analyses. In the Scandinavian dataset of 
Paper 1 and 3, 105 samples failed our individual call rate threshold of 0.80 and were 
excluded from analyses, likely reflecting diluted or low-quality DNA. Ideally, rigorous 
reassessment of DNA quality could have prompted us too seek out fresh samples from 
these individuals. The sample set from the ParkWest study and the majority of samples 
from Umeå were extracted in-house by L. Pihlstrøm by QIAamp DNA Blood Mini kit, 
yielding good quality DNA and high genotype call rates.  
Quality measures are yet more crucial for quantitative RNA analyses. For the 
gene expression experiments described in Paper 4, L. Pihlstrøm assessed the purity of 
RNA samples measured as A260/A280-ratios on a Nanodrop spectrophotometer 
(Thermo Scientific, Waltam, MA, USA). RNA integrity number (RIN) was measured 
on a Bioanalyzer instrument (Agilent, Santa Clara, CA, USA) by A. Rengmark. 
Samples extracted from frozen post-mortem tissue expectedly showed lower RIN 
values than blood RNA collected in PaxGene tubes. Brain sample RIN values in the 
range of 4.1 to 8.2 indicate RNA integrity below the ideal, yet comparable or even 
superior to reported figures from large studies in similar tissue (Trabzuni et al., 2011). 
RIN values showed no correlation with disease status or gene expression. 
Consequently, variability in RNA quality would be more likely to introduce random 
noise and type 2 error than systematic bias and type 1 error (see section 4.7 Statistical 
methods).  
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4.4 Genotyping 
SNP genotyping was performed locally by TaqMan (Paper 1) or KASPar (Paper 3 and 
4) technology on a ViiA7 instrument (Life Technologies, Foster City, CA, USA) or by
matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass
spectrometry using the Sequenom platform (Sequenom, San Diego, USA) at the
Cigene core facility, Norwegian University of Life Sciences. Sequenom technology is
based on the principle of allele specific primer extension reactions, where bases
incorporated are separated by mass. The platform allows for multiplex reactions
suitable for  medium-throughput genotyping projects. SNPs of interest for Paper 1 and
3 were submitted to Cigene, and multiplex design and genotype calling were
performed at the facility according to default software parameters. For SNPs that came
to our attention at later stages, or where Sequenom reactions were not designable,
genotyping was performed by L. Pihlstrøm using TaqMan or KASPar assays. These
are both based on PCR-reactions where allele-specific amplification is detected by
fluorescence. In TaqMan assays, a fluorescent signal is released when DNA
polymerase cleaves off the dye from the quencher of an allele-specific Minor Groove
Binding (MGB) probe. KASPar technology uses a similar principle, except the
fluorescent dyes are incorporated directly into a set of allele-specific PCR primers and
released from the quencher when amplification generates double-stranded DNA. The
results from genotyping experiments can be visualized through allelic discrimination
plots (Figure 2).
In all studies involving genotyping, we set a genotyping rate of 95% as a 
quality benchmark. As described in Paper 1, two SNPs failed to pass this criteria. One 
(rs356220) could be replaced in analysis by a different SNCA SNP, whereas the other 
(rs3129882) was regenotyped to achieve an acceptable call rate. All genotyping 
experiments included negative controls. We also analysed 87 samples as duplicates on 
the Sequenom platform without observing any discrepant genotype calls. The Hardy-
Weinberg equilibrium (HWE) is an equation that describes the relative frequencies of 
heterozygotes and homozygotes, assuming an outbred population. Departure from 
HWE may indicate genotyping error and is commonly used as a quality parameter in 
genetic association studies. In patients however, a true effect of genotype on disease 
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risk might contribute to HWE deviations. We assessed HWE in controls for all 
genotyped SNPs, observing no significant departure at a threshold of p<0.01.  
Figure 2. Allelic discrimination plot from TaqMan genotyping (rs11248051 in GAK) 
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4.5 Methylation and expression analysis by quantitative PCR 
In Paper 4, we performed qPCR on a ViiA7 instrument (Life Technologies, Foster 
City, CA, USA) to assess SNCA mRNA expression and intron 1 CpG methylation. 
Both experiments were designed and performed by L. Pihlstrøm. A range of 
methodological caveats is relevant in the context of qPCR gene expression 
experiments. Comprehensive guidelines have been published proposing a set of 
Minimum Information for publication of Quantitative real-time PCR Experiments 
(MIQE Guidelines) (Bustin et al., 2009). The common practice in scientific articles 
however, varies considerably. Firstly, it is appropriate to consider whether the sampled 
tissue is relevant for the research question of interest. We studied SNCA expression in 
a small, underpowered sample series (12 PD patients, 12 controls) from cerebral 
cortex. Tissue blocks used for RNA extraction will necessarily contain a mixture of 
cell types, introducing a possible source of noise to the expression data. The blood 
sample set was larger (36 PD patients, 36 controls), but only relevant under the 
assumption that aspects of gene regulation are equal across blood and nervous tissue. 
Levels of both α-synuclein protein and mRNA in blood have been studied in PD 
previously with variable results (Pihlstrom and Toft, 2011). SNCA mRNA is present in 
high levels in reticulocytes, but also expressed in white blood cells (Scherzer et al., 
2008). In Paper 4, we collected full blood in PAXgene tubes, while blood cell counts 
were not recorded. Consequently the potential of noisy data arising from sampling a 
mixed cell population equally applies to the blood series. 
RNA extraction is described in the previous section. RNA concentrations were 
normalized before reverse transcription. We used Applied Biosystems High Capacity 
Reverse Transcription kit according to the manufacturers instruction for cDNA 
synthesis. All gene expression assays used had primers crossing exon borders. A set of 
reverse transcriptase negative controls was run to ensure absence of amplification 
from genomic DNA. For the gene expression experiment, reactions were performed in 
technical triplicates, and any outliers in replicate groups were excluded from analysis.  
In qPCR, gene expression is measured relative to a set of reference genes. 
Reference genes, also termed housekeeping or normalization genes, are ideally 
transcribed at a stable rate across cells. Normalizing the gene of interest mRNA levels 
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to reference genes will compensate for the variability in input RNA. Which genes are 
suitable as normalizers will vary across tissues. It is currently widely accepted that 
normalization in qPCR experiments should be based on the combination of several 
housekeeping genes. Ideally, the optimal set of reference genes should be empirically 
determined for each individual study prior to the experiment itself (Vandesompele et 
al., 2002). In practice, this may often prove too resource demanding, in which case 
reference genes need to be carefully selected based on published literature. In Paper 4, 
GAPDH and HPRT were chosen for normalization in whole blood, minding the high 
levels of SNCA in reticulocytes (Silver et al., 2006). For brain normalization we used 
GAPDH, SDHA and HMBS as calibrators (Coulson et al., 2008). The normalization 
genes in qPCR expression experiments all showed pairwise coefficient of variance < 
0.5 and standard deviations of normalization factors were < 2-fold from the mean in 
both data sets, indicating stable expression (Vandesompele et al., 2009). There was no 
difference in housekeeping gene expression between groups, and RIN values did not 
correlate with expression of any gene. Results were analysed by the ΔCT-method 
using the geometric mean of all housekeeping genes as normalization factor. One out 
of several approaches to the analysis of qPCR data, the ΔCT-method relies on the 
assumption that amplification efficiency is near 100%, corresponding to a doubling of 
the PCR product with every cycle (Schmittgen and Livak, 2008). Commercially 
available gene expression probes as used here, have been validated for this method. 
For the MRSE qPCR experiment, a standard curve was performed to demonstrate 
adequate amplification efficiency. 
DNA methylation is an epigenetic modification of the cytosine base, occurring 
in relation to CpG dinucleotides. Methylation-sensitive restriction enzymes will 
recognize a short nucleotide sequence involving a CpG site and cleave the DNA strand 
only if the cytosine is unmethylated. If a qPCR targeting a differentially methylated 
region is subsequently performed, in parallel with a reference reaction of the same 
sample without restriction digestion, the fraction of cleaved versus uncleaved gDNA 
molecules can be calculated. This is the principle behind the method used to quantitate 
SNCA intron 1 methylation level in Paper 4.  Issues related to target selection and 
primer design are detailed in the article and supplement. The reactions were performed 
in technical duplicates and analysed according to the protocol for the OneStep 
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qMethyl kit (Zymo Research, Irvine, CA, USA). It should be noted that the SYTO9 
fluorescent dye used to detect amplification in the MRSE qPCR is not target specific, 
but emits a signal in the presence of any double-stranded DNA in the reaction well. 
Primer design must be optimized to uniquely target the genomic region of interest.  To 
further exclude the possibility of non-specific amplification, a melt-curve was 
performed at the end of the experiment, reflecting the composition of double-stranded 
DNA amplification products in the sample. Our initial test reactions showed an 
additional smaller peak indicating non-specific amplification. With optimization of the 
PCR cycling temperatures we obtained single peaks in all reactions (Figure 3). 
Figure 3. Melt curve analysis of the SNCA intron 1 PCR product from the same 
sample duplicate before and after optimization of cycling temperature 
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MRSE represents a rapid and affordable approach to quantitation of DNA methylation 
levels in a defined candidate region, but the method also has clear limitations. The 
methylation-sensitive restriction enzymes should preferably target several potential cut 
sites within the amplified region, in our case four motifs. The measured results 
however, will not give any information about each specific CpG site. The effect of 
anywhere between one and four cuts to a given molecule will all equally result in non-
amplification of that particular fragment. In addition there will typically be many more 
CpG sites of potential interest in the region, which are not recognized by any of the 
enzymes used. Consequently, MSRE could be regarded as a low-resolution screening 
tool for methylation assessment. Ideally, we might have included traditional bisulfite 
conversion and sequencing as a gold standard reference for at least a subset of samples 
in Paper 4. While the necessary resources for this were not available to our project, we 
note that the method has proved reliable in previous studies when methylation results 
have been validated by bisulfite sequencing in a subset of samples (Holemon et al., 
2007, Hua et al., 2011). 
4.6 High throughput sequencing 
Paper 2 reports an experiment where we performed targeted resequencing in DNA 
pools, with emphasis on methodology and study design. In Paper 3, this same 
approach is applied to investigate the coding exons of five genes at the PARK16 locus. 
Study design for the pooled sequencing experiment was done mainly by M. Toft with 
contributions from L. Pihlstrøm. DNA pooling, target enrichment and library 
preparation were performed by A.Rengmark. The sequencing was performed by the 
core facility at the Norwegian Sequencing Centre, Ullevål. L. Pihlstrøm did all 
bioinformatic analyses and was responsible for the interpretation of the results. 
High-throughput or "next-generation" sequencing (HTS or NGS) has 
revolutionized genetic research (Mardis, 2011). The crucial driving principle behind 
these technical developments has been the large-scale parallelization of reactions, 
taking place simultaneously on tiny glass plates or arrays while data is recorded. The 
major breakthrough of HTS technologies has allowed for generation of data on a 
48 
previously unimaginable scale. However, the limited availability of standardized, 
convenient tools for bioinformatic processing and interpretation of sequence data has 
arguably created a new bottleneck for genetic research. 
Traditional Sanger sequencing (Sanger et al., 1977) is still regarded the gold 
standard for both sensitive and specific sequence analysis. The error rates of different 
HTS technologies are generally somewhat higher, the major advantage being the high 
throughput. The bioinformatic processing of HTS data is to a large extent concerned 
with a range of quality metrics, all carrying important information about the 
completeness and reliability of the data. For any project using HTS, care must be taken 
to set up an appropriate bioinformatic pipeline, tailored to the relevant data and 
research questions. A range of methodological issues regarding DNA pooling, the 
choice of DNA capture technology, bioinformatic processing and quality metrics are 
discussed in detail in Paper 2. An overview of the study design is provided in Figure 4. 
While we argue that our pooled sequencing design represents a cost-effective 
and rational approach to targeted resequencing of larger sample cohorts, the work also 
has clear limitations. We reported a sensitivity estimate of 97% based on the 
assessment of eight SNPs present as single-alleles in a given pool in a total of 59 
instances. Failure to call the variant from pooled sequencing was observed only twice, 
both times in pools where the relevant position was read less than 80X, corresponding 
to < 4X per allele on average. Specificity was assessed by Sanger sequencing of pools 
positive for possibly pathogenic non-synonymous, low-frequency variants, where 17 
out of 18 SNPs were confirmed. While these results indicate good sensitivity and 
specificity, the number of investigated variants is too low for the findings to be 
confidently generalizable. Ideally, we should have obtained more comprehensive 
genotype data by an independent method, such as individual sequencing, to allow for 
statistically robust calculations of sensitivity. We might also have validated a larger 
number of detected variants within the whole target region of 71 genes, not only those 
that were possibly pathogenic within Mendelian PD genes. 
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 Figure 4. Schematic overview of the study design described in Paper 2 
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DNA pooling is a strategy motivated by the budget constraints faced by almost any 
scientist concerned with genetic research. A range of considerations apply regarding 
the overall study design, the number of individual samples combined in each pool, the 
tools used for analysis and complementary experiments to validate the results 
(Schlotterer et al., 2014). For accurate frequency estimation of common variants, large 
pools are preferred, as the inaccuracy in input DNA from each sample will tend to 
even out. In the context of rare variant discovery, it is of crucial importance that the 
sequencing error rate remains well below the expected proportion of reads represented 
by a single heterozygous variant in the pool (Figure 5). Consequently, we chose 
relatively small pools in our experiment. To confirm the individual carrier status of 
interesting variants detected in pooled sequencing, we performed Sanger sequencing 
of all 10 individual samples in the pool (Paper 2). The workload of this validation 
stage also weighed in favour of smaller pools. Primer design, PCR amplification, 
visualization of the PCR product by gel electrophoresis and data analysis in 
Sequencher 5.1 software (Gene Codes Corporation, Ann Arbor, MI, USA) were 
performed by L. Pihlstrøm, while the sequencing itself was done as a service from a 
commercial provider. 
4.7 Statistical methods 
All statistical analyses in Paper 1-4 were performed by L.Pihlstrøm. 
4.7.1 Statistical power 
In statistical hypothesis testing, two different scenarios may give rise to false 
conclusions. The incorrect rejection of a true null hypothesis is traditionally termed 
Type 1 error, while Type 2 error designates the failure to reject a false null hypothesis 
(Neyman and Pearson, 1928). When designing a genetic association study, it is of 
crucial importance to consider whether the expected sample size will give sufficient 
statistical power to answer the research question of interest (Watanabe, 2011). An 
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arbitrary, yet widely used threshold for acceptable power is 80%, implying that in the 
presence of a true disease association, the probability of observing significant results 
and rejecting the null hypothesis should be at least 80%. When the statistical power is 
lower, a negative result has very little value and may easily appear misleading, given 
the high probability of Type 2 error (false negative). In genetic association studies, the 
factors that determine statistical power are sample size, significance threshold, allele 
effect size, allele frequency, disease prevalence and genetic model. 
Figure 5. Visualization of variant reads from pooled sequencing in the Integrative 
Genome Viewer. The alignment to the reference genome of paired end reads in both 
directions are shown in pink and blue respectively. A non-reference base G>A 
appears in green on approximately 5% of reads, representing a single individual in 
the pool heterozygous for the LRRK2 G2019S mutation. The displayed reads are 
downsampled from the actual data. 
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In Paper 1, power calculations were performed using the Genetic Power Calculator 
(Purcell et al., 2003). We investigated a total of 22 loci. Based on the odds ratios 
(ORs) published in relevant GWAS, combined with allele frequencies from the present 
study and an assumed PD prevalence of 1%, our study had > 80% statistical power for 
only 10 loci. This represents a major weakness for our replication experiment, 
particularly limiting the ability to draw any firm conclusions regarding the majority of 
non-significant SNPs. We have sought to openly highlight these power issues both in 
Table 3 and the discussion section of Paper 1. Although the limitations in statistical 
power raise important concerns, there are also a few relevant considerations that may 
serve to justify the study design. While the statistical power was fully adequate for 
only 10 loci, another nine had estimated power between 50% and 80%. Of the 18 
significant GWAS hits we aimed to replicate, power was <50% for only one SNP. 
Consequently, our study could be expected to demonstrate a number of replications 
and arguably provide a valid general picture of GWAS associations in a Scandinavian 
population, even though a number of non-significant loci might be false negatives. 
Furthermore, combining association results from a range of different studies in meta-
analyses represents an important approach in genetic association research. In this 
context, a single study like ours is only one small step towards a robust international 
corroboration of a final list of susceptibility loci for PD. We provided a table with raw 
allele frequencies for all SNPs in patients and controls, suitable for meta-analysis, in 
the supplement to Paper 1. 
It should be noted that the loci which did not replicate in Paper 1 also included 
several SNPs were the estimated power to detect association was excellent. In these 
instances, there must exist a different explanation for the negative result. This 
observation motivated our extended investigation of the PARK16 locus, as reported in 
Paper 3. In Paper 4, no formal power analysis was performed. DNA methylation and 
gene expression are continuous variables, which generally tend to give better statistical 
power in small samples than binary outcomes. 
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4.7.2 Association testing 
Statistical hypothesis testing reported in Papers 1 and 3-4 were performed partly with 
the open software package PLINK (Purcell et al., 2007), and partly with IBM SPSS 
Statistics v.21 (Armonk, NY, USA). As each individual carries two alleles of each 
variant, association testing in genetic case-control studies traditionally involves 
choosing a genetic model for comparing the observed data across groups. The classical 
models are genotypic (AA vs. Aa vs. aa), dominant (AA vs. Aa+aa), recessive 
(AA+Aa vs. aa) and allelic (A vs. a). For all work presented in this thesis, we assumed 
a simple allelic model, with multiplicative (or log-additive) effects of a given allele in 
homozygous individuals.  
The most straightforward approach to association testing is the chi-square 
statistic, assessing crude differences in allele frequency between patients and controls. 
We used this test for SNP association in Paper 3. An alternative for statistical 
hypothesis testing with binary outcomes is logistic regression. A great advantage of 
logistic regression is that it allows covariates to be included and accounted for in the 
statistical model. In Paper 1, we performed logistic regression analysis with age and 
gender as covariates. This may be considered a somewhat more conservative approach 
than the chi-square test. Variability in age and gender across patient and control 
groups reflects the study inclusion practice of the collaborating centres. Unless 
migration patterns have created genetic differences between age strata in the relevant 
population, one should not expect the observed allele frequencies to be dependent on 
age or gender. Nevertheless, including these basic demographic covariables is 
common practice in genetic association studies, probably due to the large impact they 
may have in epidemiological studies concerned with environmental risk factors. 
The confounding phenomenon represents an important factor affecting the 
validity of association results in epidemiological research. Variable X may appear to 
affect a given disease of interest, when in fact, the association is driven by variable X 
being dependent on a second variable Y. The confounding of X by Y may be adjusted 
for in a regression model, yet if Y is not recorded, the study runs the risk of reporting a 
spurious association (Type 1 error). Genetic association studies represent a special 
case in this respect. As an individual's genome generally remains constant throughout 
54 
life, the potential of confusing cause and effect is limited in genetic studies. However, 
a problem may arise if patients and controls are recruited from different population 
strata with distinct genetic backgrounds. This is the genetic association study's version 
of confounding, commonly termed population stratification (Freedman et al., 2004). 
In GWAS, the genome-wide SNP dataset does in itself provide information about an 
individual's genetic background. This opens up a range of opportunities to correct for 
possible population stratification in GWAS (Zheng et al., 2006, Tian et al., 2008, 
Yang et al., 2011b), such as genomic control, principal component analysis or multi-
dimensional scaling. For studies including a limited number of markers, such as 
reported in Paper 1 and 3, this option is not available. To minimize the risk of 
population stratification, we excluded individuals of known non-Scandinavian 
ancestry. Our study included an uneven proportion of PD patients and controls from 
each collaborating site. Previous evidence has pointed to local genetic heterogeneity 
within Sweden (Humphreys et al., 2011), indicating that caution must be paid in the 
design and interpretation of genetic studies. However, in the context of larger 
association studies, the Scandinavian peninsula may reasonably be considered 
relatively homogeneous compared to other sample cohorts broadly recruited from 
Caucasian populations (Novembre et al., 2008). In Paper 1, we reran the analysis 
including study site in the logistic regression model and obtained similar results. We 
also performed Breslow-Day test for heterogeneity of association signals across study 
sites without significant SNPs. Nevertheless, it is not possible to fully exclude the 
possibility that population stratification may have affected the statistics somewhat.  
Where the case-control design is concerned with binary outcomes, Paper 4 also 
examined association with numerical outcome variables, namely DNA methylation 
and mRNA expression levels. For the blood sample analysis (N=72) we performed 
linear regression with gender and age as covariates, whereas Spearman’s rank 
correlations were calculated for the smaller brain data set (N=24). 
4.7.3 Multiple testing and significance threshold 
The issue of multiple testing is a major concern for the interpretation of quantitative 
research data (Ioannidis, 2005). As p-values represent the probability of the observed 
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data occurring by chance under the null hypothesis, seemingly "positive" results will 
expectedly follow from merely stochastic processes whenever a large number of 
hypotheses are tested. As a consequence, reliable interpretation of research data relies 
on appropriate strategies to correct for the multiple testing involved in a given project 
(Johnson et al., 2010, Rice et al., 2008). A significance level should be defined prior to 
data analysis, based on the nature of the research question and the statistical 
hypothesis testing context. 
An intuitively appealing and widely applied approach to significance level 
adjustment is Bonferroni correction, whereby the nominal significance threshold 
(classically p=0.05) is simply divided by the number of independent tests performed. 
This strategy has dominated the GWAS field, until a general consensus has more or 
less established p=5x10-8 as defining the "genome-wide significance threshold", 
regardless of the number of variants investigated (Panagiotou et al., 2012). Another 
relevant approach is permutation procedures, where the data is rearranged a large 
number of times, simulating the test distribution under the null hypothesis to generate 
an empirical p-value (Browning, 2008, Pahl and Schafer, 2010). In line with the 
principles of Bayesian statistics, the interpretation of test statistics is largely dependent 
on assumptions about the prior probabilities of a research hypothesis being true. For a 
random genomic locus in a hypothesis-free GWAS context, this probability is 
extremely small. However, in a replication study, where strong evidence has already 
nominated the candidate loci, the prior probability is much larger. For this reason, 
most GWAS follow a two-stage design, with an initial genome-wide discovery phase 
and a focused candidate replication phase (Kraft and Cox, 2008). 
In the work presented in this thesis, we aimed to rationally balance the strict 
and liberal arguments when significance thresholds were set. In Paper 1 we 
investigated 22 independent loci. We decided to highlight and report results both at the 
Bonferroni corrected (p<0.0023) and the nominal (p<0.05) significance levels. These 
differed by four versus 11 positive loci. For the discussion and interpretation of the 
findings, we found it justifiable to regard nominally significant results as supportive of 
a true association, given the context of a replication study, where previous evidence 
indicate a higher prior probability of positive findings.  
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In Paper 3, we investigated 17 SNPs, yet a considerable degree of LD was 
observed across these markers. Consequently, the SNPs are not independent, and a 
Bonferroni correction strategy is not straightforward. Given that the PARK16 region is 
robustly corroborated as a risk-locus for PD, we considered the prior possibility of true 
association to be sufficiently high to justify a nominal significance threshold in the 
SNP analysis. This liberal interpretation represents a clear limitation, however, and the 
data provide only weak support for the PARK16 signal in the Scandinavian population. 
While single SNP analyses concern only two alleles, association testing on the 
haplotype level involves comparison across a larger number of haplotypes, introducing 
more degrees of freedom to the statistics. For the more complicated test scenario of the 
sliding-window haplotype analysis reported in Paper 3, we generated empirical p-
values from 100,000 permutations, both across each haplotype window and for the 
overall experiment. The haplotype showing an experiment-wide significant empirical 
p-value (rs1572931-rs947211-rs1775143, p=0.046), also entailed a SNP reported as a
genome-wide top-hit in previous work (Lill et al., 2012), strengthening the posterior
probability of a true association. The statistical assessment of gene-gene interaction
between PARK16 and LRRK2 in Paper 3 should be regarded as exploratory and
interpreted with caution as the set of tests to be performed was not clearly defined
prior to the study, and results were marginal even without any correction for multiple
testing.
In Paper 4, the statistical testing followed a two-stage design. Bonferroni 
correction was applied in the hypothesis testing for the larger blood data set, and the 
detected association between rs3756063 genotype and methylation level was 
subsequently replicated in brain at a nomimal significance level. Although sample size 
was generally small in this study, the concordant finding observed across independent 
sample sets strengthens the overall reliability of the results.  
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5. GENERAL DISCUSSION
5.1 Corroborating and refining a list of genetic risk-loci in Parkinson's disease 
Over the recent years, results from GWAS have firmly established that multiple risk-
loci across the genome affect an individual's risk of developing sporadic PD. This 
insight provides a strong fundament for further efforts to uncover the full genetic 
architecture of PD and explore functional hypotheses about disease mechanisms and 
pathways. In contrast to early genetic association studies of candidate genes, the 
signals reported at strict genome-wide significance levels have demonstrated high 
rates of confirmatory replication in independent follow-up studies. Paper 1 represented 
a contribution to this robust corroboration of GWAS findings in PD. 
In parallel to the work described in this thesis, efforts to combine ever larger 
GWAS data sets for meta-analysis have resulted in the identification of further novel 
PD loci. The largest meta-GWAS in PD to date was published in 2014 and included 
more than 13,000 cases and 95,000 controls in the primary analysis (Nalls et al., 2014). 
Significant SNPs from the discovery phase as well as previously reported loci were 
genotyped in an independent sample set, where a total of 24 loci were replicated. In 
addition, four of these loci also showed evidence of a second, independent association 
signal when the effect of the SNP with minimum p-value was adjusted for in 
conditional analysis. 
5.2 Missing heritability 
Despite the progress achieved by large meta-GWAS, the current list of identified risk-
loci is far from a full account of the heritable variability in PD risk. Two recent studies 
have applied genome-wide complex trait analysis (GCTA) to estimate PD heritability 
from GWAS data (Do et al., 2011, Keller et al., 2012). This statistical framework 
identifies the phenotypic variance explained by genome-wide SNPs, including those 
that are not significantly associated in a traditional case-control design (Yang et al., 
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2011a). Both studies indicate a heritability of about 27%, where GWAS top-hits alone 
account for only 3-5%. Although six further loci have later been added to the list, 
these estimates still suggest that the major fraction of genetic risk in sporadic PD 
remains to be identified. Furthermore, GCTA will not take into account genetic 
variation that is not captured by GWAS genotyping arrays combined with imputation. 
Consequently, the true heritability may well be considerably higher than 27%, and the 
"missing" fraction accordingly larger. Epidemiological studies vary with respect to 
both methodology and heritability estimates, but at least some seem to support a 
higher contribution from genetic factors than the GCTA-analyses (Wirdefeldt et al., 
2011). 
5.2.1 Rare variants 
A number of hypotheses have been proposed to explain the missing heritability 
phenomenon in complex disease genetics (Manolio et al., 2009). A subset of these 
relate to the effect size and allele frequency of genetic risk variants. The GWAS 
paradigm is based on the common disease-common variant hypothesis. Basically, the 
tested markers must be fairly common in order to reach statistical significance when 
alleles are compared across cases and controls. A larger sample size will improve 
power to detect low-frequency variants or variants carrying a small effect on risk. The 
meta-GWAS by Nalls et al. detected significant SNPs of minor allele frequencies 
(MAFs) down to 0.01 when ORs were strong (1.7-1.8). By contrast, common variants 
(MAF >0.1) were significant even with ORs as low as 1.1 (Nalls et al., 2014). Figure 6 
summarizes the continuum of genetic contributions to disease, spanning from highly 
penetrant Mendelian mutations to common low-risk variants, highlighting possible 
sources of missing heritability.  
The case of heterozygous GBA mutations demonstrates that rare coding 
variants may contribute to PD without causing a Mendelian inheritance pattern. 
Association signals near SNCA and LRRK2 also indicate that the same gene may be 
implicated at several points along the effect-frequency axis with both coding and non-
coding variants affecting risk. Consequently, genes located within GWAS regions 
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provide a natural starting point for further studies of non-synonymous variation 
contributing to PD risk. 
Sequencing studies are expected to provide novel insights about the role of rare 
variants in complex diseases, including PD. HTS technologies have revolutionized 
genetic research and provided the means to produce vast amounts of data. Sequencing 
services are becoming more available and affordable, but high costs still represent a 
substantial barrier to large-scale sequencing studies. In Paper 2, we reported an 
effective study design based on high throughput sequencing and DNA pooling to 
investigate a panel of target genes in large cohorts. Subsequently, the same approach 
was used to screen for disease-relevant coding variation within the PARK16 locus in 
Paper 3. Our experiment did not identify low-frequency nonsynonymous variants of 
clear relevance to PD in PARK16 genes, indicating that the most important 
contribution to genetic risk at this locus depends on common, non-coding variation. 
These results need to be interpreted with caution, however, due to several limitations 
in study design. Although target coverage was relatively good, some regions were not 
captured, especially in NUCKS1, and relevant variants may have been missed. The 
quality measures reported in Paper 2 indicated that our study design had good 
sensitivity and specificity, yet we cannot fully exclude that PARK16 variants in 
regions of relatively low coverage may have passed undetected due to the pooling 
approach. 
Furthermore, the number of patients sequenced was moderate, limiting our 
capacity to observe variant enrichment in our samples relative to database frequencies 
below a MAF of about 0.005. Ideally, a larger number of both patients and controls 
should have been sequenced to allow for a more direct and well-powered comparison 
between groups. A more comprehensive data set would also have allowed for more 
advanced statistical approaches, in particular aggregated analyses of rare variant 
"burden" on a gene level rather than single variant association. Such statistical 
approaches are challenging, as they involve several non-trivial choices and 
assumptions, yet rare variant burden testing is becoming an increasingly important tool 
along with the widespread application of HTS in genetic research (Sham and Purcell, 
2014, Bansal et al., 2010). 
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Figure 6. The spectra of effect sizes and allele frequencies for genetic causes of PD. 
Inspired by McCarthy et al., 2008.  
Recently, several published studies have investigated rare variants in sporadic PD by 
targeted resequencing (Foo et al., 2014, Schulte et al., 2015). One study reported 
enrichment of rare functional variants in Mendelian PD genes, but not in genes at 
GWAS loci (Spataro et al., 2015). This finding is in line with our negative PARK16 
result. Future collaborative studies involving sequencing and rare variant genotyping 
of much larger sample sets could be expected to further clarify the contribution of rare 
genetic variants to PD risk. 
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5.2.2 Allelic heterogeneity 
The SNPs genotyped in GWAS each tag a set of variants in high LD at a given 
genomic locus. Any significant difference in tagSNP allele frequency is commonly 
ascribed to an unknown functional variant, driving the association signal. Allelic 
heterogeneity is present when more than one casual variant contribute to disease risk 
at the same locus. This phenomenon poses challenges to the traditional association 
study design and represents a possible source of missing heritability. The term 
"synthetic association" has been proposed for the situation where several rare causal 
variants are in LD with a single tagSNP (Dickson et al., 2010). In such cases, the 
tagSNP association will be determined by the combined contribution from all 
functional variants, weighted by effect sizes and strength of LD. If functional alleles 
with equal direction of effect tend to occur on the same haplotype, it will boost the 
observed association for a common tagSNP. Conversely, alleles with opposite effects 
on risk may neutralize each other and decimate the statistical power to detect a true 
disease association. 
The most widely appreciated approach to assess allelic heterogeneity in a 
GWAS context is stepwise conditional analysis, where the lowest p-value SNP at a 
given locus is included as a covariate in statistical testing for independent secondary 
signals. In the recent meta-analysis by Nalls et al., four out of 24 loci showed evidence 
of secondary associations at the genome-wide significance level using this approach. 
However, statistical power is reduced for every step in conditional analysis. 
Alternative bioinformatic strategies to capture the full disease-relevant variation at a 
given locus have been proposed, yet these have not been applied to large data sets in 
PD (Yang et al., 2012, Ehret et al., 2012). Genes such as SNCA and LRRK2 are already 
implicated in both Mendelian and sporadic PD, and recent studies have indicated that 
regulatory consequences of non-coding variation are widespread accross the genome 
(Thurman et al., 2012, Gaffney, 2013). It is therefore quite conceivable that important 
PD loci may harbour larger numbers of independent causal variants of different 
frequencies and effect sizes. 
Paper 3 and Paper 4 of the present thesis are both concerned with allelic 
heterogeneity of PD GWAS loci. In Paper 3, we fine-mapped the PARK16 locus and 
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found evidence of association with PD for markers located upstream of RAB7L1. 
Comparing our results to other studies, we note that SNPs highlighted as significant in 
previous reports have frequently been in low LD with this signal, including the top-hit 
from the largest GWAS meta-analysis performed in Caucasians (Nalls et al., 2014). 
We interpret this as indicative of probable allelic heterogeneity. However, robust 
significance of secondary signals in stepwise conditional analysis has thus far not been 
demonstrated for PARK16. The study reported in Paper 3 was in this respect 
unfortunately limited by sample size. Ideally, such a fine mapping study should have 
been large enough to maintain strong statistical power to detect even small effects 
when the top-hit SNP is included as a covariate. 
In Paper 4 we investigated the association between promoter methylation and 
GWAS signals of the SNCA locus, taking current evidence of allelic heterogeneity into 
account. In all published PD GWAS, the top SNCA signal has been located near the 3' 
end of the gene, represented by rs356165 in our report. A few studies have also 
detected significant secondary signals from SNPs near the 5' end of the gene. 
Interestingly, we found that promoter methylation was associated exclusively with a 5' 
risk-SNP. This observation illustrates that different functional alleles at the same locus 
probably operate through different molecular mechanisms, which may have distinct 
downstream consequences for pathogenic processes. 
5.2.3 Gene-gene and gene-environment interaction 
The simplest model of polygenic disease risk assumes a multiplicative (or log-
additive) relationship between risk alleles. As an example, carrying two risk-alleles 
each with an OR of 1.1 equals a combined OR of 1.21. In reality, this may not always 
be the case. If variants at different loci have a synergistic effect on risk, resulting in a 
larger combined effect than expected under the multiplicative model, it is commonly 
termed gene-gene interaction, or epistasis. Epistasis has been proposed as a possible 
source of missing heritability. While the notion of interaction is intuitively appealing, 
the vast number of possible hypotheses complicates statistical testing for epistasis on a 
genome-wide scale (Cordell, 2009, Wei et al., 2014). A few PD studies have 
investigated gene-gene interaction between candidate pairs of SNPs based on plausible 
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functional hypotheses (Elbaz et al., 2011). In Paper 3, we attempted to replicate a 
previously reported interaction between RAB7L1 and LRRK2 (MacLeod et al., 2013). 
Our results provided indicative evidence supporting the hypothesis that the effect of 
common variation in LRRK2 depends on the individuals' genetic risk-background at 
the PARK16 locus. These results should be interpreted with caution, as the statistical 
significance is marginal. 
Genetic risk variants may interact not only with each other, but also with 
environmental factors (Caspi and Moffitt, 2006). Gene-environment interaction may 
be exemplified by situations where a gene contributes to PD risk only under specific 
environmental circumstances, or if exposures and genetic risk variants potentiate each 
other (Ahmed et al., 2014, Hamza et al., 2014). Again, the phenomenon may represent 
a mechanism explaining missing heritability. None of the papers included in this thesis 
address gene-environment interaction directly. It might be noted, however, that the 
interpretation of Paper 4 points towards epigenetics as a possible converging 
mechanism for genetic and environmental influences on pathogenesis. The main 
finding of the article is an association between rs3756063 genotype and promoter 
methylation. Yet within each genotype group, there is still a consistent difference in 
methylation level between cases and controls, which could conceivably be driven by 
other, including environmental, risk factors (Paper 4, Figure 2).  
5.3 From association to function 
5.3.1 Loci versus genes and the limitations of fine-mapping 
For a few GWAS loci in PD, the disease-relevant genes are fairly certain. SNCA and 
LRRK2 are already implicated in monogenic PD, and coding mutations in GBA are 
established as strong risk factors. The pivotal role of the tau protein in 
neurodegenerative disease also makes it highly likely that MAPT is the responsible 
gene behind the chromosome 17 GWAS signal linked to the H1/H2 inversion 
haplotype. Various hypotheses have been put forward regarding genes in the HLA 
region on chromosome 6 (Hamza et al., 2010, Ahmed et al., 2012, Wissemann et al., 
2013). While the functionally relevant gene(s) may be debatable, at least the 
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association signal points to a pathogenic role for the immune system in PD. A 
common intronic SNP in GCH1 reached genome-wide significance in the latest PD 
GWAS meta-analysis (Nalls et al., 2014), shortly after rare, coding variants in the 
same gene were shown to be enriched in familial and early onset PD cases (Mencacci 
et al., 2014, Guella et al., 2014). This gene encodes GTP-cyclohydrolase I, a key 
enzyme in dopamine synthesis, and is furthermore known to be the cause of autosomal 
dominantly inherited dopa-responsive dystonia, a rare movement disorder which may 
exhibit Parkinsonian features (Kurian et al., 2011). Consequently, GCH1 illustrates the 
minority of cases where a novel GWAS locus immediately implicates a specific gene 
with a known function, readily suggesting further hypotheses about disease 
mechanisms. 
The above mentioned loci, however, represent the exceptions. For the majority 
of GWAS signals, the implicated genes remain unclear (Table 2). As a primary 
challenge, many associated regions contain several genes, with significant SNPs 
spread across longer stretches of high LD. Many genes encode proteins whose 
functions are unknown, making it difficult to prioritize biologically plausible 
candidates within each locus. For these reasons, it has thus far been challenging to 
map GWAS findings in PD onto protein networks, as has been done to relate genetic 
findings to relevant disease pathways in other diseases, such as multiple sclerosis 
(International Multiple Sclerosis Genetics Consortium et al., 2011). A fine-mapping 
approach is regularly employed as a first step towards a more precise localization of 
genetic association signals. Genotyping a dense panel of tagging SNPs across an 
associated locus could narrow down the observed LD block where the most associated 
SNP is located. In Paper 3, we applied this strategy to the PARK16 locus. Our data 
provide evidence in favour of an association signal located near the 5' end of RAB7L1. 
This region entails the gene promoter where non-coding genetic variation is likely to 
have functional consequences, supporting that RAB7L1 may be relevant for PD 
pathogenesis. 
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Table 2. GWAS loci in PD with examples of tentative functional hypotheses 
The listed loci correspond to the 24 signals reported as significant from the 
replication phase of the meta-analysis by Nalls et al., 2014. Loci are unsystematically 
named in the literature, typically after the closest gene(s), the most biologically 
plausible gene or in relation to chronological discovery (such as PARK16). 
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Nevertheless, fine-mapping without further functional evidence has clear limitations. 
It has been shown that a partitioning of chromosomes into neat, neighbouring blocks 
may be an oversimplification of the LD structure of the human genome (Takeuchi et 
al., 2005). The most associated SNPs may not necessarily be tagging only variation in 
the physical proximity, yet these more complex LD patterns may go undetected by 
established methods used to estimate haplotype blocks (Gabriel et al., 2002). 
Furthermore, even if the location of an association signal is narrowed down to a 
smaller region, the relevant gene may not be the closest one. Cis-acting regulatory 
mechanisms involve DNA-protein interactions over areas of several hundred kb 
(Sanyal et al., 2012). In addition, some functional mechanisms may be trans-acting. 
Fine-mapping may be valuable for identifying allelic heterogeneity. Still, as mentioned 
earlier, complex LD-association patterns may also confuse the interpretation of 
"synthetic associations" (Dickson et al., 2010). These limitations indicate that fine-
mapping data often need to be integrated with other observations in order to truly 
advance the understanding of GWAS signals in complex disease. 
5.3.2 Quantitative-trait loci 
Causal susceptibility variants in non-coding regions frequently affect gene regulation 
(Nicolae et al., 2010). Typically, genetic variants may disrupt the binding motifs of 
promoters or enhancers, thus altering the affinity of DNA-protein interactions, which 
in turn determine the rate of mRNA transcription. Genetic variants that correlate with 
a measurable quantitative trait, such as gene expression, are called quantitative-trait 
loci (QTLs). Mapping of QTLs may serve an important function in the interpretation 
of GWAS findings by linking significant loci to the regulation of specific genes 
(Cookson et al., 2009). Several large QTL datasets are now publicly available in open 
databases. It should be noted however, that where studies based on genotype may use 
any DNA, gene regulation is tissue specific. Studies indicate that regulatory QTL-
patterns that are relevant to brain disorders may be reflected in blood, yet definitely 
not always (Hernandez et al., 2012). 
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The most widely studied quantitative trait in QTL mapping has been mRNA 
expression. To better understand and interpret our association findings in Paper 3, we 
queried different PARK16 top-SNPs in publicly available datasets from monocytes 
(Raj et al., 2014) and brain (Ramasamy et al., 2014). Still, these results point to 
significant QTL-effects across several of the different PARK16 genes, further 
complicating rather than clarifying the picture. 
Regarding SNCA, evidence from families with genomic multiplications have 
indicated a dose-dependent relationship between gene transcription and disease 
severity (Farrer, 2006). Consequently, it is natural to assume that common 
susceptibility variants in the SNCA locus may lead to a more subtle increase in 
expression. Some previous studies seem to support this, yet unequivocal evidence is 
still lacking for this intuitively appealing hypothesis (Fuchs et al., 2008, Mata et al., 
2010, Nalls et al., 2011, Nalls et al., 2014). In Paper 4, we investigated SNCA mRNA, 
but were not able to demonstrate any significant association with GWAS SNPs. Our 
main hypothesis, however, was that risk variants may affect DNA methylation of a 
putative promoter in SNCA intron 1. Our results indicated that the GWAS signal from 
the 5' region of SNCA is indeed a methylation quantitative-trait locus (mQTL). 
Although our study was small, it points towards some potentially interesting novel 
insights. The findings support the hypothesis that multiple functional variants in the 
SNCA locus may influence disease risk through distinct mechanisms. Furthermore, 
promoter methylation at SNCA and other susceptibility loci represent possible points 
of interaction between genetic risk-variants, ageing and environmental exposures in 
PD. It is likely that the precise role of epigenetics in the pathogenesis of PD will be the 
focus of several large-scale studies in the future. Smaller, early reports like ours may 
have a role by inspiring study design and research hypotheses for later collaborative 
projects. 
5.3.3 Functional variation and causal mechanisms 
Even if the disease-relevant gene at a given GWAS locus could be determined with a 
high degree of certainty based on biological plausibility, fine-mapping and QTL 
analysis, a comprehensive understanding of the association signal would still require 
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the identification of the precise functional variation and casual mechanisms (Cooper 
and Shendure, 2011).  Pinpointing the responsible molecular phenomena, such as 
alterations in transcription factor binding, splicing or interactions with microRNA 
would open up for even deeper insights into the pathogenic process and also provide 
indications about systems which might be modifiable by therapy. Functional studies 
explaining the underlying mechanisms linking GWAS signals to disease are still few 
in the literature, yet some examples have demonstrated that the task is clearly feasible 
(Musunuru et al., 2010, Kulzer et al., 2014). The increasing catalogue of genomic 
annotations provided by the ENCODE project and similar experiments represents an 
important resource for generating functional hypotheses about non-coding variation 
(Kellis et al., 2014, Thurman et al., 2012, Neph et al., 2012, Encode Project 
Consortium, 2012).  
 At the onset of the present doctoral work, it was a main intention to nominate 
putative causal variants of the SNCA locus and further investigate proposed 
mechanisms in functional studies. Based on an initial fine-mapping experiment, we 
selected 48 individuals for deep sequencing of the total SNCA region, aiming to 
identify low-frequency candidate variants. Pinpointing functionally relevant variation 
from sequence data has proven complicated, and access to novel tools as well as 
findings published by others have prompted us to modify the project. While this work 
is still on-going, it is not included in the present thesis.  
 
5.4 Prospects for individual-level genetic assessment in sporadic Parkinson's 
disease 
5.4.1 Genetic score profiling 
The genetic study of complex disease is primarily justified as basic research, aimed at 
elucidating disease pathogenesis. However, with a growing number of established 
disease loci, many authors also anticipate that genetic data may become practically 
useful on an individual level, in contexts such as risk prediction, diagnosis, prognosis 
or stratification of patients in clinical research. One by one, the effect sizes of GWAS 
variants are typically far too small to have any practical value alone. In PD, no risk 
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allele identified in GWAS will give an OR>2, and most loci even well below 1.3 
(Nalls et al., 2014). Consequently, certain analyses may fruitfully be focused not on 
individual variants, but on the cumulative burden of genetic risk across a range of 
susceptibility loci. 
In Paper 1 we generated individual cumulative genetic risk scores across all 11 
loci that were nominally significant in the replication study. Our analysis showed that 
individuals within the highest risk score quintile have about a threefold risk of 
developing PD, compared to the lowest quintile. This result was in accordance with 
the corresponding figures published by others (Nalls et al., 2011), even though we 
included a smaller number of SNPs. While the method serves to illustrate the concept 
of cumulative genetic risk, the effect size would still not be useful for any individual 
prediction or diagnostics.  In the future however, it is conceivable that genetic profile 
may be successfully integrated as one of many variables in a more comprehensive 
scoring system for diagnostic or prognostic prediction purposes.  
5.4.2 Biomarkers 
As mentioned in section 1.2, the identification of informative biomarkers is an 
important aim for current PD research. Genetic data in itself could serve to classify 
individuals according to risk strata. Yet as genotypes remain constant, they will tell us 
little about on-going processes. Nevertheless, studies that largely build on genetics 
may also involve the measurement of dynamic variables, such as gene expression or 
DNA methylation, which might be conceivably be interesting as candidates for 
longitudinal biomarkers for PD pathogenesis (Karlsson et al., 2013). In Paper 4, we 
highlighted this aspect in relation to SNCA intron 1 methylation. In particular, the 
similar findings observed in blood and brain tissue was interpreted as promising, 
indicating that disease-relevant epigenetic changes may to some extent be mirrored in 
blood, which can conveniently be sampled and analysed in large numbers of patients 
at several time-points.  
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5.5 Future directions 
5.5.1 Large-scale international collaborations 
The work presented in this thesis largely builds on findings from large GWAS, 
organized as coordinated efforts within international research consortia. This 
illustrates the importance of widespread collaboration as a crucial success criterion in 
the genetic study of complex disease. Our Norwegian research group is currently 
involved as a partner in a large European project named COmprehensive Unbiased 
Risk factor Assessment of Genetics and Environment in Parkinson’s Disease 
(COURAGE-PD). This joint effort will involve identification of putative variants 
through HTS followed by large-scale validation by a customly designed genotyping 
chip in tens of thousands of samples, providing rare variant data and statistical power 
for a far more comprehensive characterization of the genetic architecture of PD than 
traditional GWAS performed to date. As part of the first subproject, all currently 
known GWAS loci will be investigated by targeted resequencing in more than 3000 
samples. This sequencing is now being performed in Oslo, with L. Pihlstrøm as the 
main responsible researcher, using the method described in Paper 2 of this thesis.  
We also have an intention to build on the experience from the work described 
in Paper 4 and design larger collaborative studies to investigate the epigenetics of PD. 
A comprehensive epigenetics project should take into account both environmental 
factors, tissue specificity and longitudinal variability in epigenetic profiles and must 
therefore involve partners collectively possessing a fruitful combination of scientific 
expertise and access to relevant biological material and data. A funding application for 
a collaborative project on the epigenetics of PD is currently in process. 
5.5.2 Functional studies 
It has been a long-term ambition for our research group to contribute to the 
characterization of causally relevant non-coding variation at the SNCA locus. Through 
this work, we have gained experience with methods for functional studies of gene 
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regulation, including DNA-protein interaction assays, cell-based assays involving 
transfection of reporter constructs and chromatin immunoprecipitation experiments. 
We will continue this work, building upon robust genetic data, aiming to pinpoint the 
functional mechanisms affecting disease risk at SNCA and/or other GWAS loci in PD.  
5.5.3 Refining genotype-phenotype correlations 
The main focus of genetic research in sporadic PD thus far has been the identification 
of variants conferring disease risk through case-control studies. However, the striking 
heterogeneity in the clinical presentation of the disorder is also likely to have, at least 
partly, genetic underpinnings. Consequently, an emerging strategy in complex PD 
genetics is to design studies where the outcomes of interest are specific subphenotypes 
or clinical variables within a patient cohort (Kasten and Klein, 2015). This approach 
may represent a first step towards disentangling the relative role of different 
pathogenic mechanisms and pathways across different subgroups of patients. Such 
stratification could have important implications for recruitment to future clinical trials, 
as treatment response to hypothetically disease-modifying therapies may depend on 
individual molecular states. Current examples of phenotype-oriented genetic studies in 
PD include investigations of cognitive function and risk variants in relevant candidate 
genes (Nombela et al., 2014), a study on motor progression and SNCA variability (Ritz 
et al., 2012) and three recent reports showing that cumulative genetic risk scores are 
associated with age at onset of PD (Nalls et al., 2015, Escott-Price et al., 2015, Lill et 
al., 2015). 
The correlations between genetic makeup and clinical phenotype in PD is a 
major area of interest for our research group, and we have several on-going projects 
aiming to study genetics in relation to novel clinical outcome variables.  
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6. CONCLUSIONS
PD is a common neurodegenerative disorder, severely affecting the quality of life of 
patients and their families. There is currently no causal treatment available to 
effectively oppose the progressive course of the disease. Our current understanding of 
PD aetiology is insufficient, and novel insights into pathogenic mechanisms and 
pathways are likely to pave way for new therapeutic strategies in the future. Genetic 
research has a major role to play in this effort to elucidate the pathogenesis of PD on a 
molecular level. With respect to the sporadic, complex form of the disease, a major 
advance in recent years has been the identification of susceptibility loci through large-
scale GWAS. However, considerable scientific efforts are necessary to refine and 
expand the understanding of GWAS association signals before the full potential value 
of these findings can be harvested for further research. The work presented in this 
thesis involves a range of different approaches, all aiming to shed further light on the 
genetic architecture of PD by building upon findings from GWAS. We provided 
further evidence for 11 GWAS loci in a Scandinavian population and presented an 
effective study design for rare variant detection within GWAS loci by targeted deep 
sequencing. Furthermore, we explored in depth the genetic variability of the 
complicated PARK16 locus and reported an association between a GWAS variant and 
promoter methylation in SNCA. Collectively, these studies touch upon many topics 
expected to become important in the next phase of discoveries in complex genetics, 
such as rare coding variants, epistasis, epigenetics and cumulative genetic risk score 
profiling. Further research following a broad range of strategies is needed to map out 
the complexities of PD and other neurodegenerative disorders and lay the groundwork 
for improved patient care in the future. 
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